Semin Liver Dis 2015; 35(04): 444-449
DOI: 10.1055/s-0035-1567827
Diagnostic Problems in Hepatology
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Hepatocellular Carcinoma Arising in an HNF-1α–Mutated Adenoma in a 23-Year-Old Woman with Maturity-Onset Diabetes of the Young: A Case Report

Ashley E. Stueck
1   The Lillian and Henry M. Stratton–Hans Popper Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York
,
Zhenhong Qu
2   Department of Pathology, Beaumont Health System, Royal Oak, Michigan
,
Mary Ann Y. Huang
3   Medical Director of Transplant Hepatology, William Beaumont School of Medicine, Royal Oak, Michigan
,
Genís Campreciós
4   Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
,
Linda D. Ferrell
5   Department of Pathology, University of California, San Francisco, San Francisco, California
,
Swan N. Thung
1   The Lillian and Henry M. Stratton–Hans Popper Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York
› Author Affiliations
Further Information

Publication History

Publication Date:
16 December 2015 (online)

Abstract

Hepatocyte nuclear factor-1α mutated hepatocellular adenomas (H-HCA) are thought to have no to minimal malignant potential. This report describes a 23-year-old woman with maturity-onset diabetes of the young who developed a 12.5-cm hepatic mass with a radiographically and pathologically distinct 3.0-cm region. Histologically and immunohistochemically, the bulk of the mass was an H-HCA with extensive pseudoglandular formation and only focal steatosis. The 3.0-cm nodule showed small cell change, thickened hepatocyte plates, pleomorphic and hyperchromatic nuclei, reticulin loss, and stromal and vascular invasion, diagnostic of hepatocellular carcinoma (HCC). Immunohistochemically, increased expression of glutamine synthetase in tumor cells and CD34 expression in sinusoidal endothelial cells were seen in the HCC component. Nuclear expression of β-catenin, and exon 3 of CTNNB1 and TERT promoter mutations were absent in this case. Thus, we report a HCC arising in an H-HCA; although cases appear exceedingly rare, they reinforce the potential of H-HCA for malignant transformation.

 
  • References

  • 1 Stoot JH, Coelen RJ, De Jong MC, Dejong CH. Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. HPB (Oxford) 2010; 12 (8) 509-522
  • 2 Zucman-Rossi J, Jeannot E, Nhieu JT , et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 2006; 43 (3) 515-524
  • 3 Bioulac-Sage P, Blanc JF, Rebouissou S, Balabaud C, Zucman-Rossi J. Genotype phenotype classification of hepatocellular adenoma. World J Gastroenterol 2007; 13 (19) 2649-2654
  • 4 Bioulac-Sage P, Balabaud C, Zucman-Rossi J. Subtype classification of hepatocellular adenoma. Dig Surg 2010; 27 (1) 39-45
  • 5 Bioulac-Sage P, Laumonier H, Couchy G , et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology 2009; 50 (2) 481-489
  • 6 Liau SS, Qureshi MS, Praseedom R, Huguet E. Molecular pathogenesis of hepatic adenomas and its implications for surgical management. J Gastrointest Surg 2013; 17 (10) 1869-1882
  • 7 Fitzgibbons PL, Bradley LA, Fatheree LA , et al. Principles of analytic validation of immunohistochemical assays: guideline from the College of American Pathologists, Pathology and Laboratory Quality Center. Arch Pathol Lab Med 2014; 138: 1432-1443
  • 8 Kazakov DV, Sima R, Vanecek T , et al. Mutations in exon 3 of the CTNNB1 gene (β-catenin gene) in cutaneous adnexal tumors. Am J Dermatopathol 2009; 31 (3) 248-255
  • 9 Koch A, Denkhaus D, Albrecht S, Leuschner I, von Schweinitz D, Pietsch T. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the β-catenin gene. Cancer Res 1999; 59 (2) 269-273
  • 10 Horn S, Figl A, Rachakonda PS , et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013; 339 (6122) 959-961
  • 11 Shafizadeh N, Genrich G, Ferrell L, Kakar S. Hepatocellular adenomas in a large community population, 2000 to 2010: reclassification per current World Health Organization classification and results of long-term follow-up. Hum Pathol 2014; 45 (5) 976-983
  • 12 Dokmak S, Paradis V, Vilgrain V , et al. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology 2009; 137 (5) 1698-1705
  • 13 Lin H, van den Esschert J, Liu C, van Gulik TM. Systematic review of hepatocellular adenoma in China and other regions. J Gastroenterol Hepatol 2011; 26 (1) 28-35
  • 14 Bacq Y, Jacquemin E, Balabaud C , et al. Familial liver adenomatosis associated with hepatocyte nuclear factor 1alpha inactivation. Gastroenterology 2003; 125 (5) 1470-1475
  • 15 Willson JS, Godwin TD, Wiggins GA, Guilford PJ, McCall JL. Primary hepatocellular neoplasms in a MODY3 family with a novel HNF1A germline mutation. J Hepatol 2013; 59 (4) 904-907
  • 16 Jeannot E, Mellottee L, Bioulac-Sage P , et al; Groupe d'étude Génétique des Tumeurs Hépatiques (INSERM Network). Spectrum of HNF1A somatic mutations in hepatocellular adenoma differs from that in patients with MODY3 and suggests genotoxic damage. Diabetes 2010; 59 (7) 1836-1844
  • 17 Bioulac-Sage P, Sempoux C, Possenti L , et al. Pathological diagnosis of hepatocellular cellular adenoma according to the clinical context. Int J Hepatol 2013; 2013: 253261
  • 18 Laumonier H, Bioulac-Sage P, Laurent C, Zucman-Rossi J, Balabaud C, Trillaud H. Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification. Hepatology 2008; 48 (3) 808-818
  • 19 Denecke T, Steffen IG, Agarwal S , et al. Appearance of hepatocellular adenomas on gadoxetic acid-enhanced MRI. Eur Radiol 2012; 22 (8) 1769-1775
  • 20 Katabathina VS, Menias CO, Shanbhogue AK, Jagirdar J, Paspulati RM, Prasad SR. Genetics and imaging of hepatocellular adenomas: 2011 update. Radiographics 2011; 31 (6) 1529-1543
  • 21 Bluteau O, Jeannot E, Bioulac-Sage P , et al. Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet 2002; 32 (2) 312-315
  • 22 Bioulac-Sage P, Rebouissou S, Thomas C , et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 2007; 46 (3) 740-748
  • 23 Raft MB, Jørgensen EN, Vainer B. Gene mutations in hepatocellular adenomas. Histopathology 2015; 66 (7) 910-921
  • 24 Pilati C, Letouzé E, Nault JC , et al. Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. Cancer Cell 2014; 25 (4) 428-441
  • 25 Bellamy CO, Maxwell RS, Prost S, Azodo IA, Powell JJ, Manning JR. The value of immunophenotyping hepatocellular adenomas: consecutive resections at one UK centre. Histopathology 2013; 62 (3) 431-445
  • 26 Fonseca S, Hoton D, Dardenne S , et al. Histological and immunohistochemical revision of hepatocellular adenomas: a learning experience. Int J Hepatol 2013; 2013: 398308
  • 27 Kakar S, Grenert JP, Paradis V, Pote N, Jakate S, Ferrell LD. Hepatocellular carcinoma arising in adenoma: similar immunohistochemical and cytogenetic features in adenoma and hepatocellular carcinoma portions of the tumor. Mod Pathol 2014; 27 (11) 1499-1509